EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

Neurodevelopmental profiles of 14 individuals with phosphomannomutase deficiency ( PMM2 ‐ CDG )

Tara Weixel iD, Dee Adedipe, Glennis Muldoon, Christina Lam, Donna Krasnewich, Audrey Thurm, Lynne Wolfe

Journal of Inherited Metabolic Disease · 2025-01 · 48 (1)

DOI: 10.1002/jimd.12782 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Journal of Inherited Metabolic Disease, online erschienen am 06.08.2024. Verfasst von Tara Weixel und 6 weiteren Autor:innen. Beteiligte Einrichtung: National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, USA. Hauptthemen laut MEDLINE: Congenital Disorders of Glycosylation, Phosphotransferases (Phosphomutases). Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Intramural NIH HHS, NIMH NIH HHS, NHGRI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PMM2‐CDG (formerly CDG‐1a), the most common type of congenital disorders of glycosylation, is inherited in an autosomal recessive pattern. PMM2‐CDG frequently presents in infancy with multisystemic clinical involvement, and it has been diagnosed in over 1000 people worldwide. There have been few natural history studies reporting neurodevelopmental characterization of PMM2‐CDG. Thus, a prospective study was conducted that included neurodevelopmental assessments as part of deep phenotyping. This study, Clinical and Basic Investigations into Known and Suspected Congenital Disorders of Glycosylation (NCT02089789), included 14 participants (8 males and 6 females ages 2–33 years) with a confirmed molecular diagnosis of PMM2‐CDG. Clinical features of PMM2‐CDG in this cohort were neurodevelopmental disorders, faltering growth, hypotonia, cerebellar atrophy, peripheral neuropathy, movement disorders, ophthalmological abnormalities, and auditory function differences. All PMM2‐CDG participants met criteria for intellectual disability (or global developmental delay if younger than age 5). The majority never attained certain gross motor and language milestones. Only two participants were ambulatory, and almost all were considered minimally verbal. Overall, individuals with PMM2‐CDG present with a complex neurodevelopmental profile characterized by intellectual disability and multisystemic presentations. This systematic quantification of the neurodevelopmental profile of PMM2‐CDG expands our understanding of the range in impairments associated with PMM2‐CDG and will help guide management strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Congenital Disorders of GlycosylationPhosphotransferases (Phosphomutases)AdolescentAdultChildChild, PreschoolFemaleHumansMaleYoung AdultDevelopmental DisabilitiesIntellectual DisabilityNeurodevelopmental DisordersPhenotypeProspective Studies

Stichwörter der Autor:innen

congenital disorders of glycosylationintellectual disabilityneurodevelopmentneuropsychological assessmentphosphomannomutase deficiency

Substanzen

phosphomannomutasePhosphotransferases (Phosphomutases)

Autor:innen und Institutionen

  • National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, USA.
  • Department of Psychological Sciences, Kent State University, Kent, Ohio, USA.
  • Neurodevelopmental and Behavioral Phenotyping Service, Intramural Research Program, National Institute of Mental Health, Bethesda, Maryland, USA.
  • Nisonger Center, The Ohio State University, Columbus, Ohio, USA.
  • Social Work, Boston, Massachusetts, USA.
  • Division of Genetic Medicine, Department of Pediatrics, University of Washington School of Medicine, Seattle, Washington, USA.

ORCID-Profile: Tara Weixel

Förderung

  • Intramural NIH HHS
  • NIMH NIH HHS
  • NHGRI NIH HHS
  • National Human Genome Research Institute
  • National Institute of Mental Health

Zitieren

APA

Weixel, T., Adedipe, D., Muldoon, G., Lam, C., Krasnewich, D., Thurm, A., & Wolfe, L. (2025). Neurodevelopmental profiles of 14 individuals with phosphomannomutase deficiency ( PMM2 ‐ CDG ). Journal of Inherited Metabolic Disease, 48(1). https://doi.org/10.1002/jimd.12782

Vancouver

Weixel T, Adedipe D, Muldoon G, Lam C, Krasnewich D, Thurm A, et al. Neurodevelopmental profiles of 14 individuals with phosphomannomutase deficiency ( PMM2 ‐ CDG ). Journal of Inherited Metabolic Disease. 2025;48(1). doi:10.1002/jimd.12782

BibTeX
@article{Weixel2025,
  author = {Weixel, Tara and Adedipe, Dee and Muldoon, Glennis and Lam, Christina and Krasnewich, Donna and Thurm, Audrey and Wolfe, Lynne},
  title = {Neurodevelopmental profiles of 14 individuals with phosphomannomutase deficiency ( PMM2 ‐ CDG )},
  journal = {Journal of Inherited Metabolic Disease},
  year = {2025},
  volume = {48},
  number = {1},
  doi = {10.1002/jimd.12782}
}
Kostenlos starten →